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Part A: Preface 
Student’s Role 
 
The Workplace Portfolio Project was completed under the supervision of Associate Professor Patrick 
Kelly (statistical supervisor) and Professor Thomas Hugh (clinical supervisor). While working full time 
at Royal North Shore Hospital as the Upper Gastrointestinal (UGI) Data Manager with Professor 
Thomas Hugh, the project commenced from August 2018 and concluded in November 2018. 
 
After discussing several ideas with Professor Hugh, we agreed to look at a project involving the liver 
resection database which is an in-house prospective clinical database that I am responsible for as 
part of my role as the UGI data manager. Dr Kai Brown (Surgical SET trainee, RNSH) had undertaken 
immunohistochemical staining of the FXYD-3 protein in patients who had undergone resection of 
colorectal liver metastases and colorectal cancer. This laboratory work was part of his PhD, but he 
had not yet analysed the data or written up this project. We elected to take on this work as my 
Workplace Portfolio Project as it provided a unique opportunity to look firstly at the prevalence and 
survival impact on FXYD-3 expression in our patient samples, and then to determine if post-resection 
systemic chemotherapy in these patients had an impact on FXYD-3 expression. Following the 
completion of this project we intend to publish this as a manuscript in a scientific peer-reviewed 
journal. 
 
In this project, my role is to undertake data collection, data entry, data management and cleaning, 
data extraction, coding as part of the liver database and coding in terms of writing the Stata 
programs, statistical analysis and writing of the report/manuscript.   
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Reflections on Learning 
 
For me this project brought together many components of research. Not only did it allow me to 
perform the data collection, cleaning and analysis but also piecing it all together and writing of a 
manuscript. The process was not easy, and we faced quite a few issues earlier on including:  
- The challenge of finding a statistical supervisor which was resolved after Associate Professor 
Kelly agreed to supervise me 
- Using data that had been matched. Initially we were missing the matched id variables which 
was rectified by Dr Brown providing me with the updated data set which included the 
matched id variables 
- Dealing with missing data which was not collected as part of our Liver database which forced 
us to impute the data on certain variables 
This project allowed me to apply the skills and knowledge that I gained from various units as part of 
my Master of Biostatistics course. A few skills that I learnt/obtained by working on this project 
include: 
- Applying the statistical concepts obtained from LCD in a matched case-control design by 
building conditional logistic regression models. 
- Obtaining a better understanding of interaction terms by working out these terms both 
manually and using Stata i.e. using the lincom command. 
- The imputation process was challenging, however an important learning curve for me. There 
were some initial issues but these were eventually overcome. Some of the problems were 
resolved myself using some debugging techniques and some with the assistance of Associate 
Professor Kelly through our regular meetings. 
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Teamwork 
 
The WPP project was completed under the supervision of Associate Professor Patrick Kelly 
(statistical supervisor) and Professor Thomas Hugh (clinical supervisor). I had regular meetings 
(fortnightly) with Associate Professor Kelly to discuss the statistical concepts to ensure I was heading 
in the right direction with my statistical analysis. I also had regular meetings with Professor Hugh to 
ensure I was discussing the correct content from a clinical point of view. 
 
Ethical Considerations 
 
Ethics was obtained by Dr Brown prior to the staining of the tumours. It was approved by the Human 
Research Ethics Committee of the Northern Sydney Local Health District.  
Student Declaration 
 
I, Nazim Bhimani sign that all the work that has been performed on this project has been carried out 
by myself with the assistance provided by my supervisors and Dr Brown for the work done in the 
laboratory. The work that I will be submitting has not been submitted previously 
 
       1 August 2018 
Nazim Bhimani      Date 
Statement by Supervisor 
 
 
 
………………………………………………..    ………………………………………… 
Associate Professor Patrick Kelly   Date  
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Abstract 
 
Background: Colorectal cancer (CRC) is the third most common cancer in Australia and 
approximately 50% of these patients will eventually develop colorectal liver metastases (CRLM) [1-
3]. Many organs such as the breast, pancreas, lung, stomach and rectum have varying expression 
levels of FXYD-3. There are conflicting results from studies examining the relationship between 
FXYD-3 expression and CRC, and to date there have been no studies on the expression of FXYD-3 in 
CRLM. 
Aims: The aim of this study is to determine the prevalence of FXYD-3 expression in patients with 
primary CRC and those that develop CRLM, and determine if FXYD-3 expression is associated with 
survival after resection of CRLM. 
Methods: A matched case-control study was conducted to compare the FXYD-3 expression between 
CRLM patients (cases) and CRC patients (controls). Conditional logistic regression was used to 
calculate p-values which are adjusted for matching. A retrospective cohort study on CRLM patients 
was used to ascertain if FXYD-3 expression was associated with overall survival. Cox proportional 
hazard models were used for the survival analysis. 
Results: Our sample consisted of 220 patients; 110 CRLM patients and 110 matched CRC patients. 
The FXYD-3 expression between CRLM patients (cases) and CRC patients (controls) showed no 
difference (p=0.62). A strong FXYD-3 expression reduces the hazard of death by 49% in comparison 
to someone who has a weak FXYD-3 expression (HR: 0.51, 95% CI 0.28, 0.93). There was evidence of 
effect modification between FXYD-3 expression and chemotherapy (p<0.001): CRLM patients with a 
strong FXYD-3 expression who received post-operative chemotherapy have longer survival 
compared to those who did not receive post-operative chemotherapy; while CRLM patients with a 
weak FXYD-3 expression who received post-operative chemotherapy after liver resection have a 
worse survival than those who did not receive post-operative chemotherapy.  
Conclusion: FXYD-3 expression is a marker for survival in CRLM patients. Post-operative 
chemotherapy is beneficial after liver resection for patients who have a strong FXYD-3 expression.  
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Introduction 
 
Colorectal cancer (CRC) is the third most common cancer in Australia and approximately 50% of 
patients eventually develop colorectal liver metastases (CRLM) [1-3]. Resection provides the best 
chance of both overall and disease-free survival. Pre-operative chemotherapy to downstage the size 
or number of tumours has become routine in patients with either up-front resectable or borderline 
resectable CRLM [4, 5]. Prognostic factors following liver resection have been identified previously. 
These include large tumours, multiple tumours, synchronous CRLMs, positive resection margins, 
extrahepatic disease and K-RAS mutation status [6-8]. Although these are helpful prognosticators, 
more accurate biomarkers are needed to assist selection of appropriate treatment as well as to 
determine prognosis [7, 9]. Frequently, chemotherapy results in debilitating side effects such as 
fatigue, hair loss, bruising, infection, nausea and vomiting, constipation, diarrhoea, peripheral 
neuropathy. Hepato-toxicity is also a concern particularly after prolonged chemotherapy (> six 
cycles) and this increases the risk of perioperative complications if patients do proceed to resection. 
Therefore the benefit of chemotherapy in improving survival may be offset in some patients [10]. 
Response to chemotherapy varies and is likely to reflect the underlying biology of the tumour.  
 
FXYD-3 is a mammary tumour protein that acts as a chloride channel or chloride channel regulator 
[11]. Many organs such as the breast, pancreas, lung, stomach and rectum have varying expression 
levels of FXYD-3. FXYD-3 is overexpressed in breast cancer [12], pancreatic ductal cancer [13], gastric 
cancer [14] and rectal cancer as well as some normal mucosal cells [15]. In normal tissues such as 
the stomach, uterus and skin, FXYD-3 has a weak expression pattern [15]. Some studies have found 
that a strong expression of FXYD-3 is associated with resistance to certain chemotherapy agents. 
However, in CRC there are inconsistent results to date. Loftas et al [16] found a strong expression of 
FXYD-3 may be an indicator of reduced radio-sensitivity and therefore reduced survival, while 
Widegren et al [15] found no correlation between FXYD-3 expression and survival. Loftas et al [17] 
also found that FXYD-3 expression had no impact on survival of patients with recurrent CRC. In 
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contrast, Simmer et al, [18] suggested that a stronger expression of FXYD-3 resulted in an increase in 
progression free of disease survival. Wang L [19] examined the prevalence of FXYD-3 in 
hepatocellular cancer (HCC) and concluded that a stronger expression of FXYD-3 correlated with 
reduced survival in HCC.  
 
The exact role of the FXYD-3 protein in patients with primary CRC is unclear, and to date there have 
been no studies in patients with CRLM. We hypothesise that FXYD-3 expression may be an 
independent predictive factor in patients who undergo liver resection and, consequently this may 
help select chemotherapy agents for subsequent treatment. Specifically, we propose that a strong 
expression of FXYD-3 may be associated with poor survival in patients with CRLM. The aim of this 
study is to determine the prevalence of FXYD-3 expression in a large sample of patients; one sample 
with primary CRC and another sample with primary CRC and corresponding liver metastases (CRLM 
patients). Specifically, we aim to see if there is a difference in FXYD-3 expression in the primary CRC’s 
of patients who did not develop liver metastases with the FXYD-3 expression in the primary CRC’s of 
patients who did develop liver metastases. Secondly, looking at a sample of patients who developed 
CRLM’s, we aim to determine if FXYD-3 expression in the primary CRC’s differed in expression in the 
corresponding liver metastases. Furthermore, we will determine if the expression of FXYD-3 might 
be used as a predictor of survival after resection of CRLM and, finally examine the relationship 
between FXYD-3 expression and the use of various chemotherapy agents in these patients. 
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Methods 
Patients 
The study population consists of patients from two separate samples who underwent resection of 
CRC on the Northern Campus of the Upper GI Surgical Unit which includes Royal North Shore 
Hospital (RNSH) and North Shore Private Hospital (NSPH). The first sample consisted of patients who 
had resection of CRC between 1998 and 2012 but who did not develop liver metastases on 
subsequent median follow up of 5.5 years. The second sample consisted of patients who underwent 
resection of a CRC between 1999 and 2012 and who then went on to develop CRLM which were 
subsequently resected. A matched case-control study was conducted to compare the FXYD-3 
expression between CRLM patients (cases) and CRC patients (controls) using 1:1 matching. Matching 
was based on age (within a three-year difference), gender, stage and grade of the primary tumour. 
The sample of CRLM patients (cases) from the matched case-control design formed our 
retrospective cohort to determine if FXYD-3 expression was associated with overall survival. 
 
Demographical patient information (age and sex), radiological (timing, primary side, tumour size, 
stage of cancer), biochemical (apical node status, BRAF status, primary tumour grade, MSI status, 
MMR status, tumour markers etc.), pre-operative treatment (radiotherapy, chemotherapy), intra-
operative details (surgical approach, blood loss, diameter of largest tumour, number of tumours, 
operation length, resection detail etc.), post-operative outcomes (complications, length of stay, 
survival, post-operative treatment - chemotherapy, SIR etc.) data on CRLM patients were obtained 
from a prospectively collected database. 
 
Immunohistochemical staining 
Immunohistochemical staining was performed using five-micrometer formalin-fixed paraffin-
embedded slides. The slides were incubated at 60 degrees Celsius for 12 hours, de-parafinised and 
then rehydrated. To obtain the antigen, the slides were then transferred to 0.01 mol/L Tris-EDTA 
acid buffer (pH 9.0) and placed on a high-pressure container for 8 minutes. This was then incubated 
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for a period of 30 minutes at room temperature followed by washing in PBS (pH 7.4). Another 
incubation period followed for 20 minutes with 3% H2O2 in methanol to block endogenous 
perioxidase activity. DAKO Protein Block serum free was used for 10 minutes to ensure non-specific 
antibody binding/staining. Once the blocking solution was removed, the slides were incubated in a 
moist chamber with a monoclonal anti-FXYD3 primary antibody in 1:2 diluted in antibody diluent 
(DAKO) overnight at 4 degrees Celsius. These slides were then incubated with a goat anti-
mouse/rabbit immunoglobulin for 25 minutes and were washed with PBS three times between each 
incubation step. The peroxidase reaction was performed for 8 minutes in 3,3 diaminobenzidine 
tetrahydrochloride (DAB) solution. The slides were rinsed with water, counterstained with Mayer’s 
hematoxylin, and then washed, dehydrated in ethanol, and mounted with xylene-based mounting 
medium. The slides which were known to show strong immunostaining for FXYD-3 were used either 
receiving the primary antibody or the universal mouse IgG as positive and negative controls. All 
positive controls produced a clear stain while all negative controls showed no evidence of staining.  
 
The slides were independently examined by two blinded investigators. In the event of lack of 
agreement between the pathologists the slides were re-stained followed by repeat examination by 
dual microscopy until an agreed score was reached. The intensity of FXYD-3 staining was scored as 
nil, low, moderate or high. The score was based off maximum intensity of staining over most of the 
slide. After excluding for non-specific straining, the grading of intensity was scored relative to 
staining patterns across all slides. The most intensely stained slides were classified as “high”. 
Fortunately, the monoclonal anti-FXYD-3 primary antibody was very specific with almost no 
background staining. Absence of staining relative to positive and negative controls was classified as 
“nil” expression. 
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Statistical Analysis 
FXYD-3 Expression 
The variable of interest was FXYD-3 expression. FXYD-3 expression slides that had a score of nil or 
low were grouped together as "weakly" stained and slides that had a moderate or high score were 
grouped together as "strongly" stained. For the CLRM patients, baseline characteristics were 
summarised according to weak and strong FXYD-3 expressions using frequencies and proportions. 
Differences in baseline characteristics between weak and strong FYXD-3 expressions were assessed 
using Pearson Chi-square or Fishers’ exact tests. 
 
Conditional logistic regression was used to examine the difference in FXYD-3 expression between the 
CRC patients who did not develop liver metastases (controls) with FXYD-3 expression in the primary 
tumours of the CRC patients who developed liver metastases (CRLM cases). Conditional logistic 
regression was used in order to adjust for the matching of controls to cases. Conditional logistic 
regression was also used to compare FXYD-3 expression in CRLM patients measured at the time of 
the primary resection and at liver resection.  
 
Overall Survival in the sample of patients who developed CRLM 
We assessed overall survival (OS) only in patients who underwent resection of CRLM using time (in 
months) from liver surgery to all-cause mortality. Kaplan-Meier curves were produced for overall 
survival by level of FXYD-3 expression. Univariable survival models were performed using the Cox 
proportional hazards model. All univariable variables that had a p-value < 0.3 were placed into the 
multivariable model. Variables with the largest p-value were removed one at a time from the 
multivariable model until we obtained a model that included FXYD-3 expression, significant 
predictors and confounders of FXYD-3 expression. A significance level of 0.05 was used for all 
analyses. A confounder was defined as a variable that changed the Hazard ratio of FXYD-3 expression 
by 20% or more once removed from the model when compared to when it was present in the 
model. Our final model consisted of Primary T stage and N stage, any recurrent disease (yes or no), 
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diameter of largest liver tumour, complications after liver surgery (None/Minor vs. Major), SIRT 
treatment (yes or no) and FXYD-3 expression. To answer our question of whether chemotherapy was 
an effect modifier, we placed post-operative chemotherapy back into the model and tested for an 
interaction with FXYD-3 expression. The proportional hazards assumption was verified using the 
Schoenfeld residuals and the overall goodness of fit of the model was assessed using Cox-Snell 
residuals. All statistical analysis was performed using Stata SE. 
 
Due to inconsistent histopathological reporting, particularly in the early years of the study period, 
some data were missing in relation to the primary tumour resection in the sample of patients who 
developed CRLM. This included the following: MMR, MSI, pattern of growth, BRAF status, apical 
node status, tumour grade, tumour size, peri-tumoural response and extramural venous 
permeation. Data in relation to the liver resection were missing in 12 patients. This included the 
duration of the operation (n=10), intra-operative blood loss (n=2), length of stay (n=1), and FXYD-3 
expression (n=12). To deal with missing data, multiple imputations were used [20]. The chained 
equations method was used by imputing 10 data sets. Imputation was based on age, sex, censor 
status, log of time to death/censored, timing of primary, primary side, primary T stage and N stage, 
operation type (laparoscopic or open), primary site, preoperative chemotherapy, tumour site of 
liver, diameter of largest liver tumour, number of liver tumours, type of liver resection, resection 
margin of liver, complications after liver surgery, pringle manoeuvre performed and post liver 
operative chemotherapy.  
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Results 
 
The study sample consisted of 220 patients; 110 patients who underwent CRC resection who did not 
develop liver metastases and 110 patients who underwent CRC resection but subsequently 
developed liver metastases. FXYD-3 expressions were obtained for 108 out of 110 CRC patients 
(98%) and 98 out of 110 CRLM patients (89%).  
 
Table 1 compares FXYD-3 expression between CRC patients (controls) and CRLM patients (cases). 
There was no difference in the staining patterns between the groups (p=0.624). The odds of low 
FXYD-3 expression compared to nil in cases is 1.04 (95% CI 0.36, 3.01) compared to the odds of low 
vs. nil in the control group. Table 2 compares the FXYD-3 expression for the CRLM patients, 
measured at time of primary resection and measured again at time of liver resection. Again, there 
was no difference in the staining patterns at both time points (p=0.548). 
 
Table 1: A comparison of FXYD-3 expression between cases and controls 
FXYD-3 expression 
in primary 
Controls (n=107) 
n (%) 
Cases (n=108) 
n (%) 
Odds Ratio 95% CI P-value 
Nil 
Low 
Moderate 
High 
9 (8) 
24 (23) 
44 (41) 
30 (28) 
8 (8) 
23 (21) 
53 (49) 
24 (22) 
Reference 
1.04 
1.34 
0.83 
 
(0.36, 3.01) 
(0.48, 3.70) 
(0.28, 2.48) 
0.624 
 
Table 2: A comparison of FXYD-3 expression between primary CRC and liver metastasis 
FXYD-3 
expression 
Primary CRC (n=108) 
n (%) 
Liver metastasis (n=98) 
n (%) 
Odds Ratio 95% CI P-value 
Nil 
Low 
Moderate 
High 
8 (8) 
23 (21) 
53 (49) 
24 (22) 
12 (12) 
17 (17) 
46 (47) 
23 (24) 
Reference 
0.46 
0.54 
0.71 
 
(0.15, 1.47) 
(0.19, 1.54) 
(0.22, 2.32) 
0.548 
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Table 3 summarises patient characteristics by FXYD-3 expression in CRLM patients of their liver 
metastases. FXYD-3 expression showed weak staining in 29 (29.6%) patients and strong staining in 
69 (70.4%) patients.  There was no significant difference in FXYD-3 expressions for sex and age 
(p>0.05). In the primary tumours, there was no difference in FXYD-3 expression in relation to the 
timing of liver metastasis (Synchronous or Metachronous), neo-adjuvant chemotherapy, tumour 
location, tumour stage, MSI Status, MMR Status, BRAF status, the pattern of tumour growth or the 
extramural venous response (p>0.05). There was a higher frequency of weak FXYD-3 expression in 
the earlier years of the sample for the primary resection i.e. 1998-2003 (37.9% vs. 10.2%, p=0.011). 
Similarly, a weak FXYD-3 expression is associated with a higher frequency of distant nodal 
metastases (N2) than a strong FXYD-3 expression (41.4% vs. 11.6%, p=0.003). From the 81 patients 
who had a recorded apical node status, a weaker FXYD-3 expression is more likely to have their 
tumour in the apical node than a strong FXYD-3 expression (20% vs. 1.8%, p=0.009). Similarly, for the 
71 patients that have a recorded tumour grade, patients with a strong FXYD-3 expression have a 
higher proportion with a Low tumour grade (69.2% vs. 44.0%), lower proportion with a Moderate 
tumour grade (13.5% vs. 44.0%) and a slightly higher proportion with High tumour grade (17.3% vs. 
12.0%) in comparison to patients with a weak FXYD-3 expression (p=0.015). For the liver resection 
there is no difference in FXYD-3 expression for any variable except year of liver resection which 
would be very close to the resection of the primary, where a higher proportion of patients with 
strong FXYD-3 expression were performed 2006-2012 (81.2% vs. 51.7%, p=0.005) in comparison to 
weak FXYD-3 expression.  
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Table 3: Patient Characteristics by FXYD-3 expression in liver metastasis in CRLM Patients 
 Total 
Population 
(n=98) 
Weak FXYD-3 
expression 
(n=29) 
Strong FXYD-3 
expression 
(n=69) 
P-value 
Patient Characteristics 
Sex 
  Male 
  Female 
 
59 (60) 
39 (40) 
 
18 (62) 
11 (38) 
 
41 (59) 
28 (41) 
0.807 
Age 
  ≤55 
  56-65 
  66-70 
  ≥71 
 
21 (21) 
26 (27) 
22 (22) 
29 (30) 
 
9 (31) 
8 (28) 
5 (17) 
7 (24) 
 
12 (17) 
18 (26) 
17 (25) 
22 (32) 
0.456 
Primary Disease 
Timing 
  Synchronous 
  Metachronous 
 
46 (47) 
52 (53) 
 
13 (45) 
16 (55) 
 
33 (48) 
36 (52) 
0.786 
Neo-adjuvant Chemo 
  Yes 
  No 
 
4 (4) 
94 (96) 
 
1 (3) 
28 (97) 
 
3 (4) 
66 (96) 
0.999 
CR Surgery Year 
  ≤2003 
  2004-2006 
  2007-2009 
  ≥2010 
 
18 (18) 
27 (28) 
24 (24) 
29 (30) 
 
11 (38) 
4 (14) 
7 (24) 
7 (24) 
 
7 (10) 
23 (33) 
17 (25) 
22 (32) 
0.011 
Primary Side 
  Right Side 
  Left Side 
 
31 (32) 
67 (68) 
 
12 (41) 
17 (59) 
 
19 (28) 
50 (72) 
0.179 
Primary T stage 
  T0, T1 or Tx, T2 
  T3 
  T4 
 
18 (18) 
49 (50) 
31 (32) 
 
5 (17) 
14 (48) 
10 (35) 
 
13 (19) 
35 (51) 
21 (30) 
0.956 
Primary N Stage 
  N0 
  N1 
  N2 
 
35 (36) 
43 (44) 
20 (20) 
 
6 (21) 
11 (38) 
12 (41) 
 
29 (42) 
32 (46) 
8 (12) 
0.003 
IHC MSI Status (n=81) 
  High 
  Low 
 
4 (5) 
77 (95) 
 
3 (11) 
24 (89) 
 
1 (2) 
53 (98) 
0.105 
Apical Node Status (n=82) 
  Not involved 
  Positive for tumour 
 
76 (93) 
6 (7) 
 
20 (80) 
5 (20) 
 
56 (98) 
1 (2) 
0.009 
Tumour Grade (n=77) 
  Low 
  Moderate 
  High 
 
47 (61) 
18 (23) 
12 (16) 
 
11 (44) 
11 (44) 
3 (12) 
 
36 (69) 
7 (14) 
9 (17) 
0.015 
BRAF Status (n=81) 
  Positive 
  Negative 
 
7 (9) 
74 (91) 
 
2 (7) 
25 (93) 
 
5 (9) 
49 (91) 
0.999 
MMR Status (n=80) 
  MMR Deficient 
 
4 (5) 
 
3 (11) 
 
1 (2) 
0.109 
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  MMR Proficient 76 (95) 24 (89) 52 (98) 
Pattern of Growth (n=61) 
  Infiltrative 
  Non-Infiltrative 
 
36 (59) 
25 (41) 
 
9 (64) 
5 (36) 
 
27 (57) 
20 (43) 
0.762 
Extramural venous permeation (n=59) 
  Present 
  Absent 
 
20 (34) 
39 (66) 
 
4 (29) 
10 (71) 
 
16 (36) 
29 (64) 
0.753 
Peritumoural Lymph response (n=59) 
  Present 
  Absent 
 
32 (54) 
27 (46) 
 
7 (50) 
7 (50) 
 
25 (56) 
20 (44) 
0.716 
Liver Metastasis 
CRLM Surgery Year 
  ≤2005 
  2006-2009 
  ≥2010 
 
27 (27) 
32 (33) 
39 (40) 
 
14 (48) 
4 (14) 
11 (38) 
 
13 (18) 
28 (41) 
28 (41) 
0.005 
Tumour markers 
  Elevated 
  Not Elevated 
 
75 (77) 
23 (23) 
 
22 (76) 
7 (24) 
 
53 (77) 
16 (23) 
0.999 
Pre-Op Chemotherapy 
  Yes 
  No 
 
70 (71) 
28 (29) 
 
24 (83) 
5 (17) 
 
46 (67) 
23 (33) 
0.143 
Surgical Approach 
  Open 
  Laparoscopic 
 
90 (92) 
8 (8) 
 
28 (97) 
1 (3) 
 
62 (90) 
7 (10) 
0.430 
Who performed the op 
  Consultant 
  Surgical Trainee 
 
78 (80) 
20 (20) 
 
22 (76) 
7 (24) 
 
56 (81) 
13 (19) 
0.553 
Hospital type 
  Public 
  Private 
 
36 (37) 
62 (63) 
 
13 (45) 
16 (55) 
 
23 (33) 
46 (67) 
0.281 
Length of Operation (n=88) 
  <120mins 
  120 ≤ mins < 180 
  180 ≤ mins < 240 
  ≥ 240mins 
 
14 (15) 
26 (30) 
26 (30) 
22 (25) 
 
5 (20) 
7 (28) 
4 (16) 
9 (36) 
 
9 (14) 
19 (30) 
22 (35) 
13 (21) 
0.227 
Cirrhotic Liver 
  Yes 
  No 
 
3 (3) 
95 (97) 
 
1 (3) 
28 (97) 
 
2 (3) 
67 (97) 
0.999 
Tumour site 
  Unilateral 
  Bilateral/Central 
 
74 (76) 
24 (24) 
 
22 (76) 
7 (24) 
 
52 (75) 
17 (25) 
0.958 
Diameter of largest tumour (mm) 
  <20 
  20≤ Diameter (mm)<30 
  30≤ Diameter (mm)<55 
  ≥55 
 
16 (16) 
27 (28) 
29 (29) 
26 (27) 
 
6 (21) 
8 (28) 
10 (34) 
5 (17) 
 
10 (14) 
19 (28) 
19 (28) 
21 (30) 
0.537 
Number of tumours 
  Single 
  Multiple 
 
52 (53) 
46 (47) 
 
16 (55) 
13 (45) 
 
36 (52) 
33 (48) 
0.786 
Vascular resection 
  Yes 
 
1 (1) 
 
0 (0) 
 
1 (1) 
0.999 
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  No 97 (99) 29 (100) 68 (99) 
Biliary Anastomosis 
  Yes 
  No 
 
1 (1) 
97 (99) 
 
0 (0) 
29 (100) 
 
1 (1) 
68 (99) 
0.999 
Resection Margin 
  R0 
  R1 
 
87 (89) 
11 (11) 
 
28 (97) 
1 (3) 
 
59 (86) 
10 (14) 
0.166 
Blood Loss (n=96) 
  0mL 
  0< Blood Loss (mL) ≤100 
  100< Blood Loss (mL) ≤300 
  >300mL 
 
18 (19) 
27 (28) 
28 (29) 
23 (24) 
 
7 (24) 
7 (24) 
5 (17) 
10 (35) 
 
11 (17) 
20 (30) 
23 (34) 
13 (19) 
0.182 
Post-operative comps 
  None/Minor 
  Major 
 
82 (84) 
16 (16) 
 
24 (83) 
5 (17) 
 
58 (84) 
11 (16) 
0.999 
Length of stay (n=97) 
  ≤6 days 
  7 or 8 days 
  ≥9 days 
 
20 (21) 
41 (42) 
36 (37) 
 
5 (17) 
14 (48) 
10 (35) 
 
15 (22) 
27 (40) 
26 (38) 
0.742 
Pringle performed 
  Yes 
  No 
 
78 (80) 
20 (20) 
 
26 (90) 
3 (10) 
 
52 (75) 
17 (25) 
0.169 
Resection Detail 
  Segmentectomy 
  Sectionectomy 
  Hemi-hepatectomy 
  Extended hemi-hepatectomy 
  Wedge 
 
28 (29) 
20 (20) 
25 (26) 
12 (12) 
13 (13) 
 
6 (21) 
7 (24) 
8 (27) 
2 (7) 
6 (21) 
 
22 (32) 
13 (19) 
17 (25) 
10 (14) 
7 (10) 
0.429 
Tumour Differentiation 
  Well 
  Moderate 
  Poor 
  N/A 
 
7 (7) 
74 (76) 
5 (5) 
12 (12) 
 
1 (4) 
21 (72) 
3 (10) 
4 (14) 
 
6 (9) 
53 (77) 
2 (3) 
8 (11) 
0.418 
Post-operative Radiotherapy 
  Yes 
  No 
 
6 (6.1) 
92 (93.9) 
 
1 (3.5) 
28 (96.5) 
 
5 (7.3) 
64 (92.7) 
0.667 
Post-operative RFA 
  Yes 
  No 
 
4 (4) 
94 (96) 
 
1 (3) 
28 (97) 
 
3 (4) 
66 (96) 
0.999 
Post-operative SIR-Spheres 
  Yes 
  No 
 
9 (9) 
89 (91) 
 
4 (14) 
25 (86) 
 
5 (7) 
64 (93) 
0.443 
Post-operative Chemotherapy 
  Yes 
  No 
 
67 (68) 
31 (32) 
 
24 (83) 
5 (17) 
 
43 (62) 
26 (38) 
0.058 
Recurrent disease 
  Yes 
  No 
 
70 (71) 
28 (29) 
 
22 (76) 
7 (24) 
 
48 (70) 
21 (30) 
0.628 
Multiple resections 
  Yes 
  No 
 
14 (14) 
84 (86) 
 
2 (7) 
27 (93) 
 
12 (17) 
57 (83) 
0.220 
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Table 4 shows the unadjusted and adjusted HR for FXYD-3 expression (see Appendix Table A1 for all 
univariable analyses). After adjusting for the significant variables in the multivariable model, strong 
FXYD-3 expression reduces the hazard of death by 58% in comparison to someone who has a weak 
FXYD-3 expression (see Appendix Table A2 for full model).  
 
Furthermore, Table 5 shows evidence that chemotherapy is an effect modifier with FYXD-3 
expression:  patients who have a weak FXYD-3 expression and have been administered 
chemotherapy are 9.38 times higher risk of death (HR=9.38 95% CI 4.91, 17.92) in comparison to 
those who did not receive chemotherapy (p=<0.001). In contrast, patients with a strong FXYD-3 
expression who were administered chemotherapy had a 50% lower risk of death (HR=0.5, 95% CI 
0.37, 0.69) in comparison to those that did not receive chemotherapy (p=<0.001) (see Appendix 
Table A3 for full model).   
 
Table 4: Hazard ratios (HR) for FXYD-3 Expression HR on overall survival for unadjusted and 
adjusted models 
HR (95% CI) Weak FXYD-3 
Expression 
Strong FXYD-3 
Expression 
P-value 
Unadjusted  1.00 0.51 (0.28, 0.93) 0.028 
Adjusted* HR (95% CI) 1.00 0.42 (0.21, 0.87) 0.019 
* Adjusted for primary T and N stage, diameter of largest liver tumour, post liver operative 
complications, recurrent disease and post liver operative SIR-Spheres 
 
Table 5: Hazard ratios (HR) for FXYD-3 Expression HR on overall survival with chemotherapy 
FXYD-3 expression No Chemotherapy** Chemotherapy** P-value P-value of 
interaction 
Weak 1.00 9.38 (4.91, 17.92) <0.001 <0.001 
Strong 1.00 0.50 (0.37, 0.69) <0.001 
** Adjusted for primary T and N stage, diameter of largest liver tumour, post liver operative 
complications, post liver operative SIR-Spheres and chemotherapy. Stratified by recurrent disease. 
 
The Cox-Snell plots indicated that the multivariable model(s) fitted the data well (see Figure A1 and 
A2 in Appendix). There is evidence of a violation of the Proportional Hazards assumption as shown in 
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Table A4 in the Appendix. We see that the interaction term between FXYD-3 and chemotherapy 
suggests a violation (borderline significant). However, the global test is not significant and when we 
look at the Cumulative incidence curve as shown in Figure 1 and Figure 2, we see that each category 
for both variables do not cross over each other and so we can say that the model produced is 
sufficient (see Figure A3 in Appendix for all Kaplan Meir curves used in the full model).   
 
Figure 1: Long term Survival by FXYD-3 expression in the Liver metastasis 
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Figure 2: Long term Survival by Post-Operative Chemotherapy and FXYD-3 expression in the Liver 
metastasis 
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Discussion 
 
In this study our aim was to determine if there is a difference in FXYD-3 expression in the primary 
tumour between patients who have CRC and did not develop liver metastasis and patients who 
developed CRLM; to see if FXYD-3 is a marker for survival in CRLM patients and to determine 
whether the administration of chemotherapy based on FXYD-3 expression impacts overall survival in 
CRLM patients. To our knowledge, this is the first study of its kind, looking specifically at a sample of 
patients with CRLM’s. Our results suggest that there is no difference in FXYD-3 expression in the 
primary tumours between CRC patients and CRLM patients. Similarly, there is no difference in FXYD-
3 expression between the primary and the liver metastases for patients who have CRLM. We have 
found that FXYD-3 expression is an independent predictor of survival without incorporating the 
effects of chemotherapy. However, interestingly a strong FXYD-3 expression was suggestive of a 
protective effect in comparison to a weak FXYD-3 expression. This was consistent even after 
adjusting for Primary T and N Stage, diameter of largest liver tumour, post liver operative 
complications, recurrent disease and post liver operative SIR-Spheres treatment. After incorporating 
chemotherapy, patients who had been administered chemotherapy after their liver resection and 
had a strong FXYD-3 expression, similarly, had a protective effect in comparison to those who did not 
receive chemotherapy. In contrast, patients who had a weak FXYD-3 expression and received 
chemotherapy after their liver resection were far worse off than patients who did not receive 
chemotherapy.  
 
With respect to primary liver tumours, Wang et al [19] discovered that a strong expression of FXYD-3 
reduces survival in patients with hepatocellular cancer (HCC) in comparison to patients with weak 
FXYD-3 expression. In contrast, there is inconsistency in the literature in relation to FXYD-3 
expression in CRC patients. Widegren et al [15] came to the conclusion that there was no 
relationship between FXYD-3 expression and CRC survival.  However, they noted that patients who 
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had a strong FXYD-3 expression and had either Dukes A or Dukes B stage were worse off than 
patients who had a weak FXYD-3 expression.  Similarly, Loftas et al [17] found that FXYD-3 
expression did not correlate with survival in patients with recurrent CRC. However, Loftas et al [17] 
defined a weak FXYD-3 expression as Nil, Low or Moderate, while in the present study and in the one 
conducted by Widegren et al [15], weak FXYD-3 expression was defined as Nil or Low. Surprisingly, 
even after altering the definitions of weak and strong FXYD-3 expression, Loftas et al [17] found the 
same outcome. Loftas et al [16] suggested a strong expression of FXYD-3 reduces the effects of 
radiotherapy and hence reduces survival in CRC patients. Simmer et al, [18] found that a stronger 
expression of FXYD-3 resulted in an increase in progression free of disease survival.  
 
There were some limitations of the present study mostly related to the relatively small data set 
consisting of only 110 patients with a significant number of predictor variables. Having a small data 
set posed a problem of whether we would be able to obtain a model for prediction with significant 
predictors and this was successfully produced. The research in itself is quite novel such that there is 
very little literature examining FXYD-3 expression in CRC patients and to date there are no studies 
that examine the impact of FXYD-3 expression in CRLM patients and their long term survival. We 
discovered that the data set consisted of missing data for the primary disease due to the lack of 
information available due to the inconsistency reported by the pathologists in the histopathology 
reports. However, we were able to overcome this problem by performing multiple imputations. 
After imputing the data, our final model consisted of variables that only had a few missing 
observations except for FXYD-3 expression which was missing for 10.9% of the data. When 
comparing the imputed model and the missing data model, our findings were consistent. During the 
analysis stage, we initially tried to differentiate chemotherapy into three groups i.e. no 
chemotherapy, chemotherapy only and chemotherapy with biological agents, however the numbers 
for each of the groups were too small to use and hence we went for a much simpler model i.e. 
chemotherapy administered, yes or no. However, even after simplifying our chemotherapy variable, 
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we had one group which only had five patients i.e. patients who had weak FXYD-3 expression and no 
post liver resection chemotherapy suggesting that we need to be careful when interpreting the 
comparison between receiving chemotherapy and not receiving chemotherapy in the weak FXYD-3 
expression group. Upon building our final model, we discovered that our model did not hold true for 
the proportional hazards assumption, however after stratifying for recurrent disease, the global test 
for the proportional hazards assumption suggested no violation. Figure 1 and Figure 2 show that the 
cumulative hazard curves do not cross over and there is no concern over the proportional hazards 
assumption. We cannot make definitive conclusions about the significance of FXYD-3 expression in 
the primary tumour cohort who did not develop liver metastases because there were only two 
deaths in this group (2%) after a median follow up of 5.6 years. In contrast, we showed that patients 
with strong expression of FXYD-3 in metastatic liver tumours had worse long-term survival than 
patients with weak expression. The reasons for this are unclear but may relate to the fact that many 
of these patients had received extensive systemic chemotherapy prior to undergoing liver resection. 
Further work is required to determine whether other factors such as gene mutation status might be 
responsible for these findings. 
 
Recommendations for future work would involve looking at a larger sample of patients to perform 
our analysis and to ensure that we have pathologists who are recording all available information into 
the histopathology reports to ensure that we have minimal missing data. Another benefit of a larger 
sample would enable us to divide the chemotherapy group as described above into three categories 
so that we see if there is a difference in patients who have had chemotherapy alone and 
chemotherapy combined with biological agents. 
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Conclusion 
  
In conclusion, we have found that FXYD-3 expression is a marker for survival in CRLM patients on its 
own. CRLM patients who have had chemotherapy and have a strong FXYD-3 expression have a 
better survival than patients with a weak FXYD-3 expression and in contrast, patients who have not 
had chemotherapy and have a strong FXYD-3 expression have a worse survival than patients who 
have a weak FXYD-3 expression after adjusting for Primary T and N Stage, diameter of largest liver 
tumour, post liver operative complications and post liver operative SIR-Spheres treatment, stratified 
by recurrent disease.  
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Appendix 
 
Table A1: Univariable results for overall survival 
Variable Hazard Ratio 95% CI P-value 
Patient Characteristics 
Sex 
  Female 
 
0.67 
 
0.35 
 
1.25 
 
0.207 
Age 
  ≥71 
 
1.70 
 
0.90 
 
3.21 
 
0.105 
Primary Disease 
Timing  
  Metachronous 
 
0.68 
 
0.38 
 
1.24 
 
0.209 
CR Surgery Year 
  2004-2006 
  2007-2009 
  ≥2010 
 
0.80 
1.19 
0.51 
 
0.36 
0.54 
0.20 
 
1.76 
2.65 
1.31 
0.310 
 
Primary Side 
  Left sided 
 
0.85 
 
0.48 
 
1.58 
 
0.612 
Primary T stage 
  T3 
  T4 
 
1.24 
2.65 
 
0.50 
1.01 
 
3.08 
6.70 
0.028 
Primary N Stage 
  N1 
  N2 
 
1.06 
2.69 
 
0.52 
1.28 
 
2.19 
5.66 
0.011 
IHC MSI Status 
  High 
 
1.59 
 
0.46 
 
5.47 
 
0.457 
Apical Node Status (n=92) 
  Positive for tumour 
 
1.82 
 
0.76 
 
4.38 
 
0.179 
Tumour Grade 
  Moderate 
  High 
 
1.18 
0.82 
 
0.60 
0.28 
 
2.35 
2.35 
0.787 
BRAF Status (n=91) 
  Positive 
 
1.68 
 
0.60 
 
4.71 
 
0.326 
MMR Status (n=90) 
  Proficient 
 
0.37 
 
0.11 
 
1.20 
 
0.096 
Pattern of Growth (n=71) 
  Infiltrative 
 
1.56 
 
0.65 
 
3.73 
 
0.321 
Extramural Venous Permeation 
  Present 
 
1.37 
 
0.66 
 
2.88 
 
0.395 
Peritumoural Lymph response 
  Present 
 
0.85 
 
0.40 
 
1.79 
 
0.659 
Liver Metastasis 
CRLM Surgery Year 
  2006 - 2009 
  ≥2010 
 
1.24 
0.78 
 
0.62 
0.35 
 
2.44 
1.74 
0.486 
Tumour markers 
  Elevated 
 
1.65 
 
0.79 
 
3.43 
 
0.180 
Pre-Op Chemotherapy 
  Yes 
 
1.34 
 
0.66 
 
2.71 
 
0.413 
Surgical Approach     
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  Open 1.52 0.37 6.33 0.562 
Who performed the operation 
  Surgical Trainee 
 
0.94 
 
0.44 
 
2.02 
 
0.872 
Hospital type 
  Private 
 
1.03 
 
0.56 
 
1.92 
 
0.917 
Length of Operation 
  120 ≤ mins < 180 
  180 ≤ mins < 240 
  ≥ 240mins 
 
1.76 
1.01 
3.25 
 
0.61 
0.33 
1.16 
 
5.04 
3.09 
9.07 
0.020 
Cirrhotic Liver 
  Yes 
 
1.77 
 
0.43 
 
7.34 
 
0.432 
Tumour Site 
  Bilateral/Central 
 
1.09 
 
0.56 
 
2.11 
 
0.798 
Diameter of largest tumour (mm) 
  20≤ Diameter (mm)<30 
  30≤ Diameter (mm)<55 
  ≥55 
 
0.67 
1.57 
1.44 
 
0.27 
0.71 
0.61 
 
1.66 
3.51 
3.40 
0.189 
Number of tumours 
  Multiple 
 
1.24 
 
0.69 
 
2.22 
 
0.479 
Vascular resection 
  Yes 
 
3.45 
 
0.47 
 
25.52 
 
0.224 
Biliary Anastomosis 
  Yes 
 
9.28 
 
1.20 
 
71.89 
 
0.033 
Resection Margin 
  R1 
 
2.11 
 
0.98 
 
4.54 
 
0.056 
Blood Loss 
  0< Blood Loss (mL) ≤100 
  100< Blood Loss (mL) ≤300 
  >300 
 
0.72 
0.87 
1.55 
 
0.29 
0.35 
0.67 
 
1.78 
2.13 
3.55 
0.275 
Post-operative Complications 
  Major 
 
1.68 
 
0.78 
 
3.62 
 
0.186 
Length of stay (days) 
  7 or 8 days 
  ≥9 days 
 
1.37 
1.95 
 
0.62 
0.88 
 
3.05 
4.36 
0.240 
Pringle performed 
  Yes 
 
0.86 
 
0.42 
 
1.80 
 
0.697 
Resection Detail 
  Sectionectomy 
  Hemi-hepatectomy 
  Extended hemi-hepatectomy 
  Wedge 
 
1.76 
1.19 
3.64 
1.89 
 
0.72 
0.47 
1.44 
0.73 
 
4.34 
3.00 
9.17 
4.92 
0.062 
Tumour differentiation 
  Moderate 
  Poor 
  N/A 
 
1.30 
2.65 
1.17 
 
0.40 
0.53 
0.29 
 
4.25 
13.21 
4.69 
0.628 
FXYD-3 expression 
  Moderate or High 
 
0.51 
 
0.28 
 
0.93 
 
0.028 
Post-Operative Radiotherapy 
  Yes 
 
0.42 
 
0.06 
 
3.06 
 
0.393 
Post-Operative RFA 
  Yes 
 
1.08 
 
0.26 
 
4.48 
 
0.914 
30 
 
Post-Operative SIR Spheres 
  Yes 
 
2.90 
 
1.39 
 
6.07 
 
0.005 
Post-Operative Chemotherapy 
  Yes 
 
1.68 
 
0.85 
 
3.33 
 
0.135 
Recurrent Disease 
  Yes 
 
6.89 
 
2.46 
 
19.32 
 
<0.001 
Multiple Liver resections 
  Yes 
 
0.60 
 
0.24 
 
1.52 
 
0.284 
 
 
  
31 
 
Table A2: Multivariable Analysis for overall survival 
 Hazard Ratio 95% CI P-value 
Primary T stage 
  T3 
  T4 
 
0.97 
3.47 
 
0.36 
1.31 
 
2.57 
9.19 
0.002 
 
Primary N Stage 
  N1 
  N2 
 
0.90 
2.30 
 
0.40 
0.98 
 
2.02 
5.38 
0.031 
Diameter of largest tumour (mm) 
  20≤ Diameter (mm)<30 
  30≤ Diameter (mm)<55 
  ≥55 
 
1.13 
1.51 
3.37 
 
0.39 
0.63 
1.12 
 
3.26 
3.63 
10.13 
0.088 
Post-operative Complications 
  Major 
 
2.93 
 
1.18 
 
7.25 
0.020 
FXYD-3 expression 
  Moderate or High 
 
0.42 
 
0.21 
 
0.87 
0.019 
Recurrent Disease 
  Yes 
 
6.48 
 
2.16 
 
19.50 
0.001 
Post-Operative SIR Spheres 
  Yes 
 
3.90 
 
1.43 
 
10.69 
0.008 
 
 
  
32 
 
Table A3: Multivariable analysis for overall survival incorporating the effects of chemotherapy 
stratified by recurrent disease 
 Hazard Ratio 95% CI P-value 
Primary T stage 
  T3 
  T4 
 
0.88 
4.29 
 
0.61 
2.89 
 
1.26 
6.37 
<0.001 
 
Primary N Stage 
  N1 
  N2 
 
0.98 
2.08 
 
0.70 
1.43 
 
1.38 
3.02 
<0.001 
Diameter of largest tumour (mm) 
  20≤ Diameter (mm)<30 
  30≤ Diameter (mm)<55 
  ≥55 
 
1.59 
1.83 
4.67 
 
1.06 
1.26 
3.09 
 
2.39 
2.66 
7.07 
<0.001 
Post-operative Complications 
  Major 
 
2.71 
 
1.97 
 
3.72 
<0.001 
Post-Operative SIR Spheres 
  Yes 
 
4.80 
 
3.16 
 
7.28 
<0.001 
FXYD-3 expression with Post op 
chemotherapy 
  Weak FXYD-3 and chemotherapy 
  Strong FXYD-3 and no chemotherapy 
  Strong FXYD-3 and chemotherapy 
 
 
9.38 
4.28 
2.14 
 
 
4.91 
2.22 
1.14 
 
 
17.92 
8.25 
4.02 
<0.001 
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Table A4: Test for Proportional Hazards Assumption 
Variable Rho Chi-Squared Degrees of 
Freedom 
P-
value 
Primary T stage 
  T3 
  T4 
 
0.02 
-0.02 
 
0.02 
0.02 
1 
1 
1 
 
0.891 
0.889 
Primary N stage 
  N1 
  N2 
 
0.05 
-0.04 
 
0.14 
0.09 
1 
1 
1 
 
0.708 
0.763 
Diameter of largest tumour (mm) 
  20≤ Diameter (mm)<30 
  30≤ Diameter (mm)<55 
  ≥55 
 
-0.15 
-0.19 
-0.22 
 
1.05 
1.69 
2.01 
1 
1 
1 
1 
 
0.305 
0.194 
0.157 
Post-operative Complications 
  Major 
 
-0.09 
 
0.58 
1 
1 
 
0.448 
Post-Operative SIR Spheres 0.04 0.07 1 0.786 
FXYD-3 expression with Post op chemotherapy 
  Weak FXYD-3 and no chemotherapy 
  Strong FXYD-3 and chemotherapy 
  Strong FXYD-3 and no chemotherapy 
 
-0.30 
-0.14 
0.02 
 
4.19 
0.81 
0.02 
1 
1 
1 
1 
 
0.041 
0.369 
0.897 
Global test 
 
13.54 12 0.331 
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Figure A1: Cox Snell Plot of final multivariable model without interaction 
 
Figure A2: Cox Snell Plot of final multivariable model with interaction 
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Figure A3: CRLM Survival by variables used in Multivariable Model 
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